Home ProductsCrotedumab (Anti-GCGR)

Crotedumab (Anti-GCGR)

Crotedumab (Anti-GCGR) thumbnail 1

GTR17287375

Crotedumab (Anti-GCGR)

recombinant-pseudotuberculosis-yersinia

Supplier ID: 957

$3,028.42($4,005.09)

Size: 25x 1 mg

Specifications

Synonyms

REGN1193

Tuberculosis (TB) remains one of the leading causes of mortality worldwide, driven largely by delayed diagnosis and the emergence of drug-resistant strains. In recent years, the development and validation of biomarkers for tuberculosis have become central to improving early detection, disease monitoring, and therapy efficacy. Whether in the context of latent TB infection (LTBI) or active pulmonary TB, identifying reliable and reproducible biomarkers is a top priority in both clinical and research settings.

Pages

Home
Products
Withdrew Requests Form

[email protected] +4924193688188

© 2026 Biomarkers of Protective Immunity Against TB . All rights reserved.